NCT04942067: Phase 1/2: APG-2575 in Combination With Novel Therapeutic Regimens in RRMM Myeloma
THE MMRF - Multiple Myeloma Immunotherapy
NCT04775550: Phase 2: DARA RVD For High Risk SMM (PRISM)
NCI National Cancer Institute: Manufacturing CAR T Cells to Accelerate Cancer Immunotherapy Research
Multiple Myeloma Research Foundation - MMRF - Genomics
Patient Symposium - MCRT Webcast Myeloma Crowd Round Table, 05/08/2021, Dana-Farber Cancer Institute
NCT04939844: Phase 2: REST - Replacing Steroids in the Transplant Ineligble (REST)
NCT04843579: Phase 2: Selinexor in Combination With Clarithromycin, Pom & Dex RRMM - ClaSPd
NCT04802356: Phase 2: Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma
Multiple Myeloma Research Foundation - MMRF - Clinical Trials
What is the MMRF CureCloud®? Welcome to the MMRF CureCloud! Multiple Myeloma Research Foundation
American Cancer Society - www.cancer.org: What is CART Cell Therapy?
NCT04935580: Phase 1/2: Study of FasT CAR-T GC012F Injection in High Risk TE NDMM Patients
Patient Symposium - MCRT Webcast Myeloma Crowd Round Table, 04/24/2021
THE MMRF - Multiple Myeloma Autologous Stem Cell Transplantation
Multiple Myeloma Research Foundation - MMRF -Autologous Hematopoietic Stem Cell Transplantation ASCT
NCT04879043: Phase 1/2: Study to Assess Safety of HDP-101 in Patients With RRMM
Roswell Park - What is a Clinical Trial? Clearing Up Common Misconceptions
Expanded Access Protocol for Receiving Idecabtagene Vicleucel That is Nonconforming for commercial